The FDA has approved Bayer’s treatment for hot flashes caused by menopause, bolstering the company’s women’s health portfolio. Bayer said Friday that Lynkuet is the first dual neurokinin-targeted therapy to win …
Microsoft Issues Emergency Patch for Critical Windows Server Bug
Microsoft initially fixed CVE-2025-59287 in the WSUS update mechanism in the October 2025 Patch Tuesday release, but the company has now issued a second, out-of-band update for the flaw, which is under attack in the wild.
FDA uncovers unauthorized Indian API warehouse with lizards, cats
The FDA sent an unusual inspection report late last month to the Indian generic drugmaker Hetero Labs after uncovering an unauthorized warehouse holding drugs and active pharmaceutical ingredients (APIs) that was also infested with lizards …
Halda reveals first clinical data of RIPTAC drug in prostate cancer
Halda Therapeutics, a startup developing a new class of small molecule drugs to target and destroy cancer cells, has unveiled a promising first cut of data from an ongoing study in prostate cancer. The New …
How CISA Layoffs Weaken Civilian Cyber Defense
Cyber teams need to get to work backfilling diminishing federal resources, according to Alexander Garcia-Tobar, who shares clear steps on a path forward for protecting enterprises with less CISA help.
Philly is on Lilly’s radar for next Gateway Labs site
Eli Lilly is considering the City of Brotherly Love as a possible next home for its next Gateway Labs site. The pharma giant recently posted a job opening for the “site …
Shutdown Sparks 85% Increase in US Government Cyberattacks
Attackers are pouncing on financially strapped US government agencies and furloughed employees. And the effects of this period might be felt for a long time hereafter.
Lilly expands gene therapy work with Adverum acquisition
Eli Lilly is bolstering its gene therapy portfolio at a time when other large drugmakers are reassessing their work in the complex and commercially challenging field. The Indianapolis-based drug giant
FDA rejects Sydnexis’ myopia drug for kids; Chugai to buy Renalys for $98M upfront
Plus, news about Kura Oncology, X4 Pharmaceuticals, Coya Therapeutics, Harbour BioMed and Silver Creek: 👁️ FDA rejects Sydnexis’ experimental myopia drug: The company said the regulator does not believe the data …
Biogen pays $70M upfront to Vanqua Bio for immunology drug
Biogen is giving C5aR1 another go. It’s paying $70 million upfront to Vanqua Bio for exclusive global rights to the Chicago startup’s preclinical C5aR1 antagonist dubbed VQ-201 and up to …